Penson, Richard T

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 2,279

Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer

Krasner, C. N., Campos, S. M., Young, C. L., Chadda, K. R., Lee, H., Birrer, M. J., Horowitz, N. S., Konstantinopoulos, P. A., D'Ascanio, A. M., Matulonis, U. A., et al. (2021) · Gynecologic Oncology

Ovarian cancer diagnosis and treatmentCancer therapeutics and mechanisms

Cited by 42

Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer

Penson, R. T., Ambrosio, A. J., Whalen, C. A., Krasner, C. N., Konstantinopoulos, P. A., Bradley, C., Matulonis, U. A., & Birrer, M. J. (2023) · The Oncologist

PARP inhibition in cancer therapyOvarian cancer diagnosis and treatment

Cited by 12